PosterSessionOnline

EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER

EASL Congress 2026

27-30 May, Barcelona

N. Poster

Poster title

Applicant name

Status


FRI-3	A systematic review of digital health tools and early real-world experience with HepB&Me application in chronic hepatitis B to tackle the unmet clinical need	Almuthana Mohamed	Received

THU-3	Evolving impact of alcohol and abdominal adiposity on liver mortality in Finland over four decades: implications for public health interventions	Fredrik berg	Received

SAT-3	Risk of advanced fibrosis and cancer in a population-based colorectal cancer screening program: implications for EASL case-finding strategies	David Marti-Aguado	Received

LBP-8	longitudinal multi-omics reveals regenerative programs and predictive plasma signatures in human liver regeneration	martin cornillet	Received

WED-8	Perspectives of people living with hepatitis B towards long-acting antivirals: a global study	Su Wang	Received

FRI-10	Decentralised HBV, HCV, and HIV screening among migrant and refugee populations in Portugal and Spain: results from VH-COMSAVAC	Aina Nicolàs Olivé	Received

FRI-12	Low treatment rates observed in an analysis of the chronic hepatitis B care cascade at a tertiary medical center in a major metropolitan area in the US	Kevin Pak	Received

SAT-12	Patient pathways for rare liver diseases: development of a European template	Sarah Raevens	Received

FRI-13	Prevalence and socioeconomics of hepatitis D virus coinfection in two Southern California counties	Kevin Pak	Received

THU-13	Mapping receptivity and susceptibility to new models of care for metabolic dysfunction-associated steatotic liver disease (MASLD) across Europe: a mixed-methods, landscaping study	Leonard Broekman	Received

SAT-15	Multidisciplinary assessment of unemployment risk factors in liver transplant recipients: final results of the RICReaTI project	Margherita Saracco	Received

FRI-15	Predictors of hepatitis B infection and vaccination coverage in sub-Saharan Africa: case studies from Gabon and Mauritania using Demographic and health Survey data	Jodi Palmer	Received

TOP-16	Socio-demographic inequalities on the UK liver transplant waiting list over time: the impact of prognostic scores and candidate selection schemes	Ji Jade King	Received

TOP-17	Feasibility and outcomes of liver health checks in community alcohol services	Daniel Gutmann	Received

TOP-18	Increased diagnosis and risk stratification for MASLD in primary care over the last 20 years: real-world evidence from over 11.7 million individuals in the UK	Huei-Tyng (Philippe) Huang	Received

THU-19	Sexual function in chronic liver disease: a case-control study	Yooyun Chung	Received

WED-20	Evaluation of sex-based differences on hepatitis B, C and D viruses´ disease burden and cascade of care in Italy	Samantha Hall	Received

THU-20	An interpretable artificial intelligence framework for cardiovascular risk prediction in metabolic dysfunction-associated steatotic liver disease: LiverCARD	antonio cirella	Received

THU-22	Trends in hospitalizations and in-hospital mortality due to primary biliary cholangitis in Brazil (2015–2024): a decade of real-world evidence from the public unified health system	Cláudia Couto	Received

SAT-22	Trends in mortality due to liver neoplasms in Portugal (2013-2022): a decade of rising challenges	Mario Jorge Silva	Received

THU-27	Stable alcohol consumption over time in older adults, assessed by PEth	Marie Fredriksson	Received

WED-29	Population-based hepatitis C screening and elimination program in Lithuania: may it affect the incidence of hepatocellular carcinoma?	Limas Kupcinskas	Received

SAT-31	Validated early detection metrics reduces the population requiring liver fibrosis screening	Laurens Van Kleef	Received

TOP-33	Non-genetic determinants of hepatitis B surface antibody disappearance in Taiwan´s vaccinated generations	CHUN-YI CHANG	Received

SAT-35	Impact of fibrotic MASH as a new indication on semaglutide eligibility in the U.S. adult population	Laurens Van Kleef	Received

SAT-36	Artificial intelligence in scientific abstract review: complement or contradiction to human judgment? Insights from a Latin American hepatology cohort	Maria Lynch-Mejia	Received

SAT-37	Excess mortality from cirrhosis by neighbourhood deprivation, aetiology, and clinical presentation: a Swedish register-based cohort study	Juan Vaz	Received

SAT-38	Socioeconomic disparities in access to curative treatment among individuals with surveillance-detected hepatocellular carcinoma in Sweden: a nationwide cohort study	Juan Vaz	Received

WED-38	From control to elimination of HCV infection: the experience in prisons of Catalonia, Spain	Andrés Marco	Received

THU-38	Real-world epidemiology and clinical outcomes in MASLD: A 20-year nationwide analysis of over 23 million individuals in Taiwan´s national health insurance research database	Huei-Tyng (Philippe) Huang	Received

THU-39	Outcomes and all-cause mortality in people with MASLD in UK primary care: a real-world matched cohort study of 1.8 million individuals	Huei-Tyng (Philippe) Huang	Received

SAT-39	Burden, trends and projections of liver cancer in China and G20 countries: a comparative study based on the global burden of disease database 2023	Yikai Wang	Received

SAT-40	Burden, trends and projections of cirrhosis in China and G20 countries: a comparative study based on the global burden of disease database 2023	Yikai Wang	Received

LBP-41	HSK31679, a thyroid hormone receptor beta agonist, improves histological outcomes in Asian patients with MASH and F2–F3 fibrosis: a 52-week phase 2b randomized, double-blind, placebo-controlled trial	Feng Xue	Received

SAT-41	Inefficiency of risk-based screening for steatotic liver disease in primary care: a multi-cohort analysis of more than 15,000 individuals	Bernhard Wernly	Received

SAT-42	Estimation of liver fibrosis risk using non-invasive biomarker tests in people living with HIV and pre-diabetes in Tanzania	Trenton White	Received

THU-42	Mental distress and social support in adult offspring of parents with alcohol-related liver disease compared to offspring of parents with a cancer diagnosis: a national health survey	Pernille Jessen	Received

THU-47	Effectiveness of a smartphone-assisted lifestyle intervention program on weight reduction: a retrospective study	Stanislav Kravchuk	Received

WED-51	Clinical characteristics of patients with low liver stiffness measurement (LSM) on VCTE and biopsy-proven at-risk MASH on biopsy	Elizabeth Brombosz	Received

FRI-54	Community-based alcohol-related liver disease early recognition and assessment (CALDERA): effect on drinking behaviour, markers of liver injury and emergency hospital attendance	Ewan Forrest	Received

SAT-57	Drug-induced liver injury: a survey among members of the society of liver disease in Africa	Maurizio Bonacini	Received

SAT-58	Our experience of immune-mediated hepatotoxicity: five-year data from a London cancer centre	Annabelle Chung	Received

FRI-62	Impact of on-demand nalmefene–mediated alcohol reduction on liver function and noninvasive fibrosis and steatosis measures in patients with alcohol use disorder and metabolic dysfunction–associated alcohol-related liver disease	Yohei Koizumi	Received

WED-62	Definite fibrotic metabolic-dysfunction associated steatohepatitis in referrals at center in Denmark	Mark Berner Hansen	Received

TOP-63	Prognostic performance of liver stiffness changes in patients with biopsy-proven cirrhosis secondary to metabolic dysfunction-associated steatohepatitis	Jimmy Che-To Lai	Received

TOP-65	Universal FIB4 screening, automated secondary care referral, new cACLD & HCC identified; benefits of integrated MASLD screening within the precision iDiabetes platform	Damien Leith	Received

THU-68	Alarmin interleukin-33 protects against liver injury and promotes hepatocyte proliferation in acute liver failure	Mengqi Li	Received

THU-70	Construction of engineered biliary trees with P-glycoprotein efflux function and enhanced resistance to drug-induced injury	Shiwen Ma	Received

SAT-70	Clinical relevance of albumin binding kinetics in patients undergoing extracorporeal albumin detoxification	Stine Koball	Received

WED-73	Metabolic and cognitive effects of a 6-month dietary intervention in patients with MASLD: a prospective study	Gian Paolo Caviglia	Received

WED-75	Comparison of clinical care pathways for metabolic dysfunction-associated steatotic liver disease (MASLD) in type 2 diabetes (T2D) in the dawn of effective pharmacological therapy	Wah Kheong Chan	Received

FRI-78	Long-term mortality under the new steatotic liver disease classification	Sakkarin Chirapongsathorn	Received

FRI-79	Higher socioeconomic position is associated with alcohol under-reporting relative to PEth	Helle Schnefeld	Received

WED-85	Deep learning integration of nuclear magnetic resonance metabolomics and NASH-FibroTest biomarkers improves blood-based prediction of liver fat measured by magnetic resonance imaging	Olivier Deckmyn	Received

THU-87	Liver metabolic stress and fibrosis modify APOE e4–associated cognitive vulnerability and amyloid burden	Young Hyeon Ahn	Received

SAT-87	Individualised treatment benefit of double plasma molecular adsorption system in patients with liver failure	Yee Hui Yeo	Received

FRI-88	Triglycerides identify a lower-risk phenotype and predict mortality in clinically suspected alcohol-associated hepatitis	Ana Suárez-Saro Fernández	Received

THU-90	Missed opportunities to diagnose metabolic dysfunction associated and alcohol associated steatotic liver disease after incidental detection in the emergency department	Qusai Al Zureikat	Received

WED-91	A new definition of burning-out MASLD using albumin and amino acid imbalance	Hideki Fujii	Received

SAT-92	The single-cell landscape of MASLD-enriched liver sinusoidal endothelial	DAE WON JUN	Received

SAT-95	Dysregulation of the E2F2-PCSK9 axis promotes MASLD progression and related cardiovascular disease	Maider Apodaka-Biguri	Received

TOP-96	Can reliably measured transient elastography be trusted in obesity? Comparing the modifying effects of general and central adiposity in MASLD	Fredrik berg	Received

TOP-97	Assessment of cardiometabolic comorbidities and the impact of glycemic and weight control on liver stiffness in advanced metabolic dysfunction-associated steatotic liver disease	Cautar El Maimouni	Received

WED-100	A novel machine learning-based algorithm improves risk stratification of patients with MASLD compared to FIB-4	Kamela Gjini	Received

FRI-100	Cell-free DNA as a biomarker of liver fibrosis in alcohol-related liver disease	Paola Zuluaga Blanco	Received

FRI-102	Hepatic stellate cell-derived Follistatin-like 3 ameliorates alcohol-induced liver injury via inhibition of Activin type II receptor signaling pathway	Gloria Alvarez-Sola	Received

SAT-103	Epigenetic programming of metabolic liver disease by early-life nutritional overload	claudia bigas	Received

SAT-104	Global analysis of protein post-translational modifications reveals novel regulatory mechanisms in steatotic liver disease	Virginia Aranda	Received

SAT-107	Protease driven phenotypical changes in lipid associated macrophages attenuates metabolic dysfunction associated steatohepatitis progression	Júlia Cacho-Pujol	Received

THU-107	Stronger association and causal link between visceral adipose tissue and metabolic dysfunction-associated steatotic liver disease in women, particularly after menopause	Yutian Cao	Received

WED-115	Prediabetes identifies a high-risk subgroup for advanced liver fibrosis in non-diabetic MASLD: a non-invasive risk stratification study	Trung Huynh	Received

WED-118	Prognostic significance of a 5 kPa absolute change in liver stiffness measurements (LSM) to predict liver-related events in patients with compensated advanced metabolic dysfunction-associated steatotic liver disease (MASLD)	Xinrui Jin	Received

THU-119	Association between sex and long-term clinical outcomes in metabolic dysfunction-associated steatotic liver disease	Pojsakorn Danpanichkul	Received

SAT-121	The chronic environmental exposure to Bisphenol A influences trained immunity-related pathways and induces immunometabolic innate cells reprogramming, promoting the metabolic dysfunction associated steatotic liver disease (MASLD) progression	Marcello Dallio	Received

WED-122	Optimal cut-off of 2D shear wave elastography for ruling out significant hepatic fibrosis in MASLD: a meta-analysis and machine learning	DAE WON JUN	Received

FRI-126	Binge alcohol exposure induces neutrophil extracellular trap associated injury in the proximal small intestine	Scott Minchenberg	Received

WED-127	Emerging indices outperform traditional fibrosis scores in young MASLD across divergent screening goals	Ahlim Lee	Received

TOP-128	An artificial intelligence model to better predict hepatocellular carcinoma risk in patients with metabolic dysfunction-associated steatotic liver disease: a large-scale 20-year cohort study	Ming-Ying Lu	Received

THU-131	Vitamin D insufficiency is associated with liver fibrosis development in people with HIV	Francesca Farina	Received

THU-133	Depression and anxiety levels are higher in obese women than in men in a cohort of MASLD patients	Marta Guariglia	Received

SAT-134	Ultrastructural analysis of transjugular biopsies in metabolic dysfunction-associated steatotic liver disease identifies core hepatocellular stress adaptations	Jose Fortea	Received

SAT-139	The liver RNF43-Wnt/ß-catenin pathway remotely regulates the intestinal inflammation repair pattern through bile acid reprogramming	Ying Geng	Received

THU-140	Steatotic liver disease as an upstream risk factor for the development of metabolic syndrome–related disorders: a 7-year health checkup cohort study in Japan	Yoshihiro Kamada	Received

FRI-140	Isotemporal associations of sedentary behavior and physical activity with health-related quality of life in patients with metabolic dysfunction-associated steatotic liver disease	Abdullah Alansare	Received

FRI-147	Efficacy of a therapeutic physical exercise program in patients with metabolic dysfunction–associated steatotic liver disease: a randomized, open-label, bicenter study (SteatoAPA)	Rodolphe Anty	Received

SAT-147	Lack of MASP-3 ameliorates liver injury and fibrosis in diet-induced fatty liver via modulation of apoptosis and inflammatory pathway in mice	Manabu Hayashi	Received

THU-147	Long-term association between Helicobacter pylori serostatus changes and incident metabolic dysfunction–associated steatotic liver disease	HAE YEON KANG	Received

THU-149	Impact of endothelial dysfunction on disease progression in patients with MASLD and microalbuminuria	Hijran Khidirova	Received

FRI-151	Which comes first: GLP-1 RA vs resmetirom in MASH real world practice	Ana Maria Davila Morales	Received

THU-151	MASLD and coronary calcification: how Bayesian analysis supports the association	Florian Koutny	Received

FRI-153	Treatment with naltrexone/bupropion enhances lifestyle-induced improvements in hepatic steatosis in adults with overweight/obesity	Carmen Dietvorst	Received

WED-154	FIB-4 reflex testing in patients with diabetes mellitus at the primary care level allows calculation of referral rates to specialized care and allocation of resources	Eva Katharina Messer	Received

FRI-157	Habitual aspirin use and MRI-derived liver fat and fibroinflammation	Qi Feng	Received

THU-159	Brief alcohol counseling in steatotic liver disease: a single-center observational study of six-month changes in alcohol use, noninvasive liver metrics, and quality of life	Erica Nicola Lynch	Received

TOP-161	Maternal metabolic dysfunction-associated steatotic liver disease rewires placental-fetal selenium crosstalk and mediates fetal liver insulin resistance	Simran Sharma	Received

FRI-163	Cost-effectiveness of resmetirom treatment, aligned with practice guidance, for suspected ´At-Risk MASH´ identified by transient elastography without histologic confirmation	DAE WON JUN	Received

SAT-164	Imeglimin attenuates liver injury in a nondiabetic mouse model of MASH by restoring mitochondrial function	Kosuke Kaji	Received

SAT-165	Multi-compartment dissection of bile acid remodeling reveals mechanistic drivers of MASLD progression	DAE WON JUN	Received

WED-166	Is perfection the enemy of good? A streamlined screening strategy for metabolic dysfunction-associated steatotic liver disease in the community	TD Clara Nguyen	Received

WED-167	The influence of stress factors on the state of the intestinal microbiota and intestinal epithelial permeability in patients with metabolic dysfunction-associated steatotic liver disease	Yana Nikiforova	Received

THU-171	The journey of MASLD: the implementation gap between guidelines and primary care in linkage to care	DAE WON JUN	Received

SAT-172	GPR84 antagonism shifts liver macrophage polarization from M1 to M2, increases liver triiodothyronine, and improves cholesterol levels and hepatic steatosis in a high-fat diet metabolic dysfunction-associated steatohepatitis mouse model	Martin Leduc	Received

THU-173	Estimated glomerular filtration rate and urine albumin-creatinine ratio trajectories in young adulthood and midlife metabolic-dysfunction associated steatotic liver disease: the coronary artery risk development in young adults study	Seong Park	Received

WED-174	Machine learning prediction of liver fibrosis in patients with metabolic dysfunction associated steatotic liver disease (MASLD)	Grazia Pennisi	Received

WED-179	Head-to-head comparison between FibroTest and ELF, for the fibrosis diagnostic in outpatients with type-2 diabetes, using Bayesian latent class models	Valentina Peta	Received

THU-179	Ethnic differences in non-invasive tests, disease severity, and liver-related outcomes in a diverse Canadian population with metabolic dysfunction-associated steatotic liver disease	Keyur Patel	Received

THU-182	The relationship between endothelial dysfunction, insulin resistance, and metabolic associated steatotic liver diseases	Kateryna Pivtorak	Received

FRI-184	Effects of SGLT-2 inhibitors on clinical outcomes in patients with MASLD and type 2 diabetes mellitus: a nested case-control study using LIFE study data	Eiichi Ogawa	Received

WED-185	Comparison of MASLD characteristics in patients with type 1 and 2 diabetes mellitus	Donovan Richelle	Received

WED-189	Lysosomal acid lipase activity as a marker of advanced fibrosis in steatotic liver disease: a prospective study	Tarek Saadi	Received

THU-191	Assessment of maternal and fetal outcomes of pregnancy in metabolic associated fatty liver disease, a prospective cohort study	Hend Shousha	Received

TOP-193	Serum glycomics at admission predict liver transplantation-free survival in patients with acetaminophen-induced acute liver failure	Lorenz Grossar	Received

SAT-198	Metabolic ferroptosis as targetable signature for the genetic subtype of MASLD	erika paolini	Received

SAT-201	Single-cell integration of transcriptomics and mtDNA sequencing identifies pan-cellular mosaic mitochondrial heteroplasmy as a hallmark of MASH	Carlos Pirola	Received

FRI-204	FB7033: A novel siRNA dual-targeting Hydroxysteroid 17-beta Dehydrogenase 13 (HSD17ß13) and cell death-inducing DFF45-like effector B (CIDEB) exhibits potential for treatment of metabolic dysfunction-associated steatohepatitis (MASH)	Michael Wang	Received

FRI-205	SGLT2 inhibitors and risk of major adverse liver outcomes in patients with chronic liver disease and type 2 diabetes	Axel Wester	Received

WED-205	Comprehensive risk assessment for gastrointestinal cancers in steatotic liver disease (MASLD, MetALD, and ALD)	Nobuharu Tamaki	Received

WED-211	Prognostic value of liver stiffness measurement for liver-related events in metabolic dysfunction-associated liver disease-related compensated advanced chronic liver disease	Kessarin Thanapirom	Received

WED-215	Simplified metabolic dysfunction associated fibrosis-5 (sMAF-5) score to identify at-risk liver fibrosis and to predict prognosis	Laurens Van Kleef	Received

THU-216	Evaluating gastrointestinal bleeding risks and esophagogastroduodenoscopy requirement in low-risk hepatocellular carcinoma patients undergoing atezolizumab and bevacizumab: interim analysis	Laia Aceituno	Received

WED-216	Evaluating non-invasive screening strategies for identifying treatment-eligible fibrotic MASH in MASLD patients	Laurens Van Kleef	Received

THU-217	The VETC-associated trabecular subtypes in non-cirrhotic HCC is defined by loss of tumor suppressor and downregulation of ribosomal genes	Khushboo Agrawal	Received

THU-218	Predicting transcatheter arterial chemoembolization response in hepatocellular carcinoma using a two-stage imaging framework with automated liver segmentation and bidirectional temporal difference modeling	Geng-Hao Bai	Received

TOP-224	Inhibition of protein kinase C-? as a strategy to overcome steroid resistance in severe alcohol-related hepatitis	Manisha Yadav	Received

WED-225	Real-world liver fibrosis screening patterns of adults with type 2 diabetes and cirrhosis: a population-based Canadian cohort	Cindy Wen	Received

FRI-225	Durvalumab–Tremelimumab in advanced hepatocellular carcinoma: real-world data From the LOR-HCC (Lombardy, Italy real-world HCC group)	Lorenzo Canova	Received

THU-227	Predicting decompensation in unresectable hepatocellular carcinoma on immunotherapy: the ARTE score	Lorenzo Canova	Received

WED-229	Referral burden and second-tier testing in two-step algorithms for detecting significant hepatic fibrosis among Asian community-based type 2 diabetes mellitus	DAE WON JUN	Received

WED-232	TP53/ARID1A-driven macrotrabecular and TERT/BAP1-enriched microtrabecular tumors represent two distinct histomorphological subtypes of non-cirrhotic hepatocellular carcinoma	Khushboo Agrawal	Received

WED-234	Identification of novel therapeutic agents using patient-derived organoids in HCC	Reha Akpinar	Received

FRI-234	Transjugular intrahepatic portosystemic shunt as a bridging strategy to hepatocellular carcinoma treatment in patients with refractory ascites or hydrothorax	Camille Imparato	Received

FRI-237	First-line therapy in super-older adults with hepatocellular carcinoma: comparative effectiveness of Lenvatinib versus Atezolizumab-Bevacizumab	Masamichi Kimura	Received

THU-237	Hepatocellular carcinoma risk prediction score : a novel artificial intelligence model for hepatocellular carcinoma risk assessment in hepatitis C patients	Eslam Elmasry	Received

FRI-244	Efficacy of second-line therapies and the prognostic value of the crafity score in advanced hepatocellular carcinoma following Atezolizumab plus Bevacizumab failure: a real-world study	Jinpeng Li	Received

FRI-245	Radiotherapy with Atezolizumab and Bevacizumab and Survival in Advanced Hepatocellular Carcinoma	Gyungsun Lim	Received

THU-246	Machine learning-enhanced serum FTIR spectroscopy analysis for diagnosing hepatocellular carcinoma in cirrhotic patients	Elia Gigante	Received

SAT-246	High burden of depression, sleep disturbance, and anhedonia in primary biliary cholangitis independent of fibrosis stage and prognostic scores	Gupse Adali	Received

FRI-249	Real-world outcomes of sequential transarterial chemoembolization followed by Atezolizumab–Bevacizumab in patients with unresectable hepatocellular carcinoma	Soe Thiha Maung	Received

SAT-251	S-adenosyl-L-methionine improves health-related quality of life in patients with primary sclerosing cholangitis and inflammatory bowel disease: a subanalysis of a randomized, placebo-controlled trial	Emil Bik	Received

WED-252	Platelet-induced mitochondrial transfer promotes hepatocellular carcinoma progression	Shuangsuo Dang	Received

FRI-252	First-line Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in Egyptian patients with unresectable hepatocellular carcinoma: a retrospective real-world study	Ehab F. Moustafa	Received

THU-253	Study of the prevalence of hereditary hemochromatosis (HFE) and secondary causes of hiperferritinemia in patients participating in a bloodletting programme	Agustin Castiella	Received

THU-259	Clinical characteristics of alpha-1 antitrypsin deficiency patients and coexistence of metabolic dysfunction-associated steatotic liver disease	Maria Del Barrio	Received

SAT-260	True seronegative autoimmune hepatitis in adults is rare and overestimated	Francesca Colapietro	Received

THU-261	Structured transition care program for chronic liver disease: a 6-Year clinical audit demonstrating superior outcomes	Victoria Ekstrom	Received

FRI-262	Pathogenic MUC1? cholangiocytes drive fibrogenic crosstalk via the EFNA5–EPHA2 axis in cholestatic liver injury	Aishwarya Bhatnagar	Received

THU-265	Quantitative histological evaluation reveals duct paucity in children with severe alpha-1 antitrypsin deficiency (Pi*ZZ genotype)	Malin Fromme	Received

FRI-266	Identification of molecular targets from the interactome of primary sclerosing cholangitis and their therapeutic modulation	Claudia Fuchs	Received

FRI-268	T helper cells influence the fate decision of facultative liver stem cells	Ben Higgins	Received

SAT-268	Reassessing the utility of the Ferritin-IgG score in predicting complete biochemical response in patients with autoimmune hepatitis from the ColHai registry: is it truly useful?	Alvaro Diaz-Gonzalez	Received

THU-269	Haemodynamic alterations associated with hepatic vascular malformations in hereditary haemorrhagic telangiectasia: a cohort study	Pernille Darre Haahr	Received

WED-271	Circulating lipid signatures drive mitochondrial stress and inflammatory remodelling in non-cirrhotic MASLD-associated hepatocarcinogenesis	Jian Huang	Received

FRI-272	Methyldopa reduces plasma bile acid concentrations in a murine model of estrogen-induced cholestasis	Dina Manna	Received

WED-272	Enhanced detection of hepatocellular carcinoma using combined biomarker panels including alpha-fetoprotein, alpha-fetoprotein-L3, des-gamma-carboxyprothrombin and the galad score	Van Trung Huynh	Received

SAT-274	Long term prognostic impact of persisting histological activity despite biochemical remission in autoimmune hepatitis (AIH)	Sarah Flatley	Received

SAT-275	Long-term extrahepatic mortality in autoimmune hepatitis: a cohort study	Sarah Flatley	Received

THU-276	Safety of infliximab in sarcoidosis and effect on hepatic involvement – a retrospective cohort study	Elizabeth Low	Received

TOP-277	Real-world effectiveness and safety of seladelpar in primary biliary cholangitis: a nationwide electronic health record-based study	Adrielly Martins	Received

TOP-278	Factors associated with the development of primary biliary cholangitis in individuals with antimitochondrial antibodies: a spanish multicenter study	Alvaro Diaz-Gonzalez	Received

WED-282	Visualizing and quantifying brain copper retention in Wilson disease models: a 64Cu PET study	Nicole Antolini	Received

THU-283	Exploring pregnancy among Wilson disease patients in Europe: results from a health-care providers´ exploratory survey from the ERN RARE-LIVER consortium	Zoe Mariño	Received

SAT-283	Unmet needs of patients with primary biliary cholangitis in Greece: results from the preliminary analysis of the Hellenic autoimmune liver diseases study group	Nikolaos Gatselis	Received

WED-284	High copper levels induce oxidative stress and inflammatory processes in a cell culture model of Wilson´s disease	Ruth Broering	Received

WED-287	Hepatocyte-specific CNNM4 silencing alleviates liver injury in alpha-1 antitrypsin deficiency	Nerea Ferreiro	Received

THU-289	Utility of using modified Leipzig score for diagnosis of Wilson´s disease in a resource-limited setting	Yumnah Riaz	Received

FRI-290	Multi-omics analysis reveals zone-specific hepatocyte antigen presentation and pathogenic CD8+ T cells in autoimmune hepatitis	Han Wang	Received

TOP-292	Statin use is associated with reduced cholangiocarcinoma risk in primary sclerosing cholangitis: a national EHR cohort study	Miki Scaravaglio	Received

TOP-294	The number needed to treat with bezafibrate as second-line therapy to prevent liver transplantation or death in people with primary biliary cholangitis	Ellen Werner	Received

TOP-295	Centrally-imprinted innate immune tolerance following colitis attenuates cholestatic liver disease: implications for gut-liver axis driven PSC-IBD pathogenesis	Rania Matthys	Received

TOP-296	Liver-specific CNNM4 silencing alleviates fibrosis by restoring bile acids homeostasis in cholestatic preclinical models and human liver slices	Naroa Goikoetxea-Usandizaga	Received

THU-299	Genome-wide association study to identify novel genetic variants associated with primary Budd-Chiari syndrome	Shalimar Shalimar	Received

SAT-302	The mean corpuscular volume (MCV) is a surrogate for therapeutic azathioprine metabolites in patients with autoimmune hepatitis	Guan Sen Kew	Received

FRI-302	Inhibiting cuproptosis mitigates cholangiocyte inflammation in primary biliary cholangitis	Yu-Jie Zhou	Received

TOP-309	Genetic testing reveals hidden genetic diseases in adult patients with idiopathic chronic cholestasis and chronic hepatitis with unknown aetiology	Ignasi Olivas	Received

TOP-310	Two-fold improvement of thrombosis regression rate after implementation of a multidisciplinary treatment protocol for acute superior mesenteric vein thrombosis	Sophie Ciere	Received

FRI-314	Targeting TRIM54: a potential protective strategy against liver injury in cirrhosis	Fan-E Cheng	Received

SAT-323	Impact of imaging surveillance on outcomes after cholangiocarcinoma diagnosis in primary sclerosing cholangitis	Adrielly Martins	Received

SAT-324	Latent class analysis identifies three distinct patient phenotypes in primary sclerosing cholangitis: implications for clinical trial access and mental health screening	Adrielly Martins	Received

WED-324	Human liver spatial transcriptomics reveals macrophage-driven antiviral responses distinguishing seronegative fulminant hepatitis from autoimmune hepatitis	Amber Bozward	Received

TOP-325	Time-resolved single-cell profiling of liver fibrosis regression identifies monocyte-derived Kupffer cells as central mediators of resolution	Katharina Bonitz	Received

FRI-330	The platelet-derived growth factor receptor beta binding vector "Fibrobody®", for clinical targeting of liver fibrosis	Sylvia Klomp	Received

WED-332	Hepatitis B virus specific T cell immunity to guide discontinuation of nucleoside analogue therapy in hepatitis B e antigen negative chronic hepatitis B	Raquel Encijo-Heredia	Received

SAT-334	Rifaximin ameliorates liver fibrosis and hepatocarcinogenesis in experimental MASH by inhibiting the gut–liver axis and Epiregulin–IL-8–driven angiogenesis	Kosuke Kaji	Received

WED-337	Retinoids reprogram TREM2? monocyte-derived macrophages toward a restorative phenotype via redox control to attenuate liver fibrosis	Kyurae Kim	Received

THU-338	MAVS-dependent type I interferon mediated non-viral liver injury and hepatocarcinogenesis upon hepatic autophagy inhibition	Lea Aylin Yücel	Received

TOP-342	Hepatic B cells interact with invariant natural killer T cells via CD40 to stimulate hepatic stellate cells	Jihyo Byun	Received

TOP-344	SIRT4 enhances NK cell cytotoxicity against hepatic stellate cells and reverses liver fibrosis via the AMPKa/p53/NKG2DL axis	Huan Chen	Received

WED-345	PD-1+ follicular helper T cells as the key discriminator: a combined model with plasmablasts for distinguishing autoimmune hepatitis from drug-induced liver injury	Zikun Ma	Received

SAT-348	Diet and exercise mitigate MASLD and exert beneficial effects on skeletal muscle via organ crosstalk in diet-induced obese mice	Vanessa Souza-Mello	Received

WED-352	Collectin-11 of the lectin pathway mediates complement-dependent hepatic ischemia-reperfusion injury in mice	Tatsuro Sugaya	Received

SAT-353	Gut microbiota metabolite butyrate ameliorated acute-on-chronic liver failure by regulating macrophage polarization	Jing Xiao	Received

WED-355	Targeting the STING pathway as a strategy to suppress hepatitis B virus replication	Mingyuan Zhang	Received

WED-356	VISTA deficiency exacerbates the development of acute-on-chronic liver failure by promoting Tc1 differentiation	Yao Zhang	Received

TOP-359	Prospective multicenter evaluation of prototype deep learning algorithms versus liver imaging reporting and data system (LI-RADS) criteria in diagnosing hepatocellular carcinoma on computed tomography	Rex Wan-Hin Hui	Received

SAT-361	Bridging the gap in primary sclerosing cholangitis care: results from a patient survey	Adrielly Martins	Received

THU-362	mRNA COVID-19 vaccination shortly after PD-1/PD-L1 inhibitor Is associated with better survival in liver cancer: a Mayo Clinic platform study	Yuting Huang	Received

THU-363	Serum exosome-related lipids could detect MASLD-associated hepatocellular carcinoma	Jian Huang	Received

THU-364	Intensive care admission patterns and outcomes in hepatocellular carcinoma patients on systemic therapy	Rex Wan-Hin Hui	Received

FRI-370	Prognostic and predictive value of single-nucleotide polymorphism signature in patients with resected hepatocellular carcinoma: a multicentre retrospective study	Xiao-Peng Tian	Received

TOP-373	A confidence-aware artificial intelligence pathology model for cholangiocarcinoma diagnosis	Yue Cheng	Received

TOP-375	Prognostic impact of neoplastic portal vein thrombosis and extrahepatic metastases in advanced hepatocellular carcinoma receiving Atezolizumab–Bevacizumab: a multicenter real-world study	Filippo Cattazzo	Received

FRI-379	Comparison of surgical resection, percutaneous ablation, and transarterial chemoembolization for hepatocellular carcinoma patients with recompensated cirrhosis: a multicenter, retrospective, cohort study	Can Zhang	Received

WED-380	Single-cell transcriptomic profiling of endothelial-to-mesenchymal transition in MASLD-associated liver carcinogenesis	Victoria Priori	Received

FRI-382	Neurofilament light chain proteins are a sensitive biomarker of neuronal damage in hepatic encephalopathy	Clelia Asero	Received

THU-382	Performance of HCC risk scores in patients with advanced chronic liver disease: a multicenter cohort study	Mohamed Moussa	Received

THU-383	Addition of the GAAD score to imaging improves classification of non-cirrhotic focal liver lesions	Mohamed Moussa	Received

WED-385	Galectin-3 inhibition supports HCC growth via pro-tumorigenic liver reprogramming	Paul Schneider	Received

FRI-385	Serum-conditioned nanoplastics trigger hepatocyte injury and inflammation in human liver tissue	Paula Boeira	Received

THU-387	Identify liver tumors from ultrasound images through ensemble learning integrated with the ordered weighted averaging operator	Hsiao-Ching Nien	Received

FRI-388	Maladaptive emergency myelopoiesis is already activated in patients with the less severe forms of acutely decompensated cirrhosis, and its amplification drives progression towards severity	Zhujun Cao	Received

TOP-390	Using patient-led genetics to identify new therapeutic targets in metastatic cholangiocarcinoma	Paula Olaizola	Received

FRI-395	Recapitulating cirrhosis in vitro using a primary liver microphysiological system and patient plasma profiling	Laura de Jong	Received

FRI-397	Increased ceftriaxone exposure in hospitalised patients with decompensated cirrhosis compared to patients without cirrhosis revealed by population pharmacokinetic modelling (TACTILE study)	Solaiman Ezzafzafi	Received

THU-397	Imaging spectrum of giant hepatic hemangioma with diffuse hepatic hemangiomatosis: nine case series	Ki Choon Sim	Received

THU-398	Hepatocellular carcinoma in Budd Chiari syndrome: characteristics and risk factors	MARINELA STOIAN	Received

TOP-407	Development and validation of a novel pretreatment MRI-based radiomic model to predict progression after thermal ablation in early stage hepatocellular carcinoma using data from two randomised control trials	Mathew Vithayathil	Received

TOP-408	Efficacy and feasibility of neoadjuvant immunotherapy in hepatocellular carcinoma	Sarah Cappuyns	Received

FRI-409	Insulin-like growth factor 1 suppression worsens with cirrhosis severity and mortality, and therapeutic restoration improves outcomes in decompensated cirrhosis: a clinical-experimental study	Parminder Kaur	Received

SAT-411	Long-term outcomes of autoimmune hepatitis: complications, cancer risk and survival in a large nationwide swedish cohort	Richard Thörn	Received

FRI-411	Systemic markers of fibroblast- and immune cell activity in post-TIPS endotyping within patients with severe clinical evolution	Diana Leeming	Received

WED-412	CAND1 as a novel therapeutic target in pediatric hepatoblastoma: linking NEDDylation to tumor progression	Leidy Estefanía Zapata-Pavas	Received

THU-414	Exploring practices and attitudes towards stopping hepatocellular carcinoma surveillance: a multinational clinician survey with over 500 respondents	Georgia Zeng	Received

WED-415	Clostridioides difficile mortality in cirrhotic patients matches other bacterial infections in the antimicrobial resistance era	Alexandra Alexopoulou	Received

SAT-416	Metabolic syndrome as a determinant of inadequate biochemical response to ursodeoxycholic acid in primary biliary cholangitis	Christos Triantos	Received

WED-417	Is 100 the new 250? Ascites fluid PMN >100 has the highest predictive value and odds for 30-day mortality in a national cirrhosis cohort undergoing paracentesis	Jasmohan Bajaj	Received

SAT-417	Presence of myopathy in patients with primary biliary cholangitis	Yigit Sahin	Received

WED-418	Dynamic assessment of the AMMON model can guide preventative therapies of patients at risk of liver-related events	Maria Pilar Ballester	Received

SAT-419	Recurrence rate and clinical outcomes for recurrent primary sclerosing cholangitis after liver transplantation: a systematic review with meta-analysis	Lisa Laforce - van Lierop	Received

TOP-422	Epigenetic dysregulation of the IL1B-driven inflammatory program drives resistance to anti–PD-1 therapy in hepatocellular carcinoma	Wenying Qiao	Received

TOP-423	Therapeutic plasma exchange improves short-term survival in acute on chronic liver failure: a randomised controlled trial	Sagnik Biswas	Received

THU-426	Efficacy and safety of endoscopic and endovascular interventions for secondary prophylaxis of gastric varices in patients with cirrhosis: systematic review and individual patient data meta-analysis	Sagnik Biswas	Received

WED-426	Effects of GLP-1 receptor agonists on the progression of metabolic chronic liver disease.	Montserrat Camps Fajol	Received

SAT-428	Differentiating acute-onset autoimmune hepatitis from drug-induced autoimmune-like hepatitis: a multicenter study and score development	Haoyu Wen	Received

WED-430	Computed tomography-defined sarcopenic obesity: an emerging risk factor for cardio-cerebrovascular mortality in cirrhosis	Yanhua Chen	Received

FRI-434	Targeting disrupted immunometabolism-induced mitochondrial bioenergetic failure using YAQ006 and YAQ005 reduces mortality in ACLF	Supachaya Sriphoosanaphan	Received

FRI-435	Ammonia-induced mitochondrial bioenergetic failure is driven through a TLR4-dependent mechanism that specifically targets Complex IV	Supachaya Sriphoosanaphan	Received

THU-435	Prevalence and risk factors of esophageal and gastroesophageal varices in myeloproliferative neoplasm patients with portal hypertension in a tertiary government hospital: a 5-year cross-sectional study	Sam Fandood	Received

FRI-441	Targeting glycolytic rewiring rescues liver sinusoidal endothelial cell mitochondrial bioenergetics and vascular barrier integrity mitigates endotoxin mediated portal hypertension in cirrhosis	Vaibhav Tiwari	Received

SAT-441	One in four adults have already developed cirrhosis at the time of primary biliary cholangitis diagnosis among a national cohort of veterans in the United States	Robert Wong	Received

FRI-444	Data-driven biomarker phenotypes refine risk stratification in advanced chronic liver disease	Adrian Wunderbaldinger	Received

WED-444	Comparative assessment and external validation of ultrasound-derived quadriceps indices against bioelectrical impedance analysis for sarcopenia screening in chronic liver disease	Paolo Gallo	Received

SAT-445	Clinical characteristics and predictors of poor biochemical response in patients with primary biliary cholangitis: a single-centre study from Xinjiang, China	Caihua Chang	Received

FRI-447	Fenofibrate is associated with improvement in chronic cholangiopathy after liver transplantation: a single-center experience	Fredrik berg	Received

FRI-448	Donor and recipient pharmacogenetic variation at the POR locus is associated with acute rejection and biliary strictures after liver transplantation	Fredrik berg	Received

THU-448	Diabetes is an independent risk factor for hepatic encephalopathy and death in patients undergoing TIPS placement	Lukas Hartl	Received

THU-449	TIPS facilitates recovery from different types of hepatorenal syndrome and may improve clinical outcomes in patients with HRS-AKI	Lukas Hartl	Received

SAT-449	Alterations in primary hemostasis in patients with liver cirrhosis and bacterial infection	Alexandra Alexopoulou	Received

SAT-451	Validation of consensus liver failure cut offs to predict 30-day mortality in a nationwide inpatient cirrhosis cohort	Jasmohan Bajaj	Received

SAT-452	Immune failure in ACLF: validation of consensus definitions in two large cohorts of inpatients with cirrhosis	Jasmohan Bajaj	Received

FRI-452	Intrahepatic low shear–induced mitochondrial redox dysfunction in liver sinusoidal endothelial cells drives microvascular dysfunction and contributes to acute portal hypertension	Rajni Yadav	Received

WED-453	Elevated growth differentiation factor 15 reflects disease-driving mechanisms in cirrhosis and predicts liver disease progression and mortality	Benedikt Hofer	Received

TOP-454	Impact of apixaban on hepatic decompensation in cirrhosis (ApiHep): a randomized controlled trial	Ayush Agarwal	Received

TOP-455	Pre-treatment serum albumin concentration predicts clinical outcomes in patients with cirrhosis receiving long-term albumin	Enrico Pompili	Received

TOP-456	Prognostic impact and predictive factors of cardiac decompensation following TIPS implantation in cirrhosis– data from the multicenter CARTIPS study	Medizinische Hannover	Received

THU-458	Quantifying the morbidity and mortality of decompensated liver cirrhosis in Australia	Angus Jeffrey	Received

FRI-461	Safety and efficacy of GLP-1 receptor agonists in liver transplant recipients: a multi-national experience	Chiara Becchetti	Received

THU-463	Combining different non-invasive tests stratifies the risk of clinically significant portal hypertension (CSPH) in patients with compensated advanced chronic liver disease (cACLD)	Jimmy Che-To Lai	Received

THU-466	The differential effects of terlipressin on serum sodium trajectories are mediated by ascites status, treatment indication and baseline sodium	Dorothy Liu	Received

FRI-467	Secretin therapy during ex-situ normothermic liver machine perfusion: a critical factor for restoration of bile duct physiology and the protective "bicarbonate umbrella"	Roberto Broere	Received

FRI-468	Clinical outcomes of sequential hypo- and normothermic machine perfusion versus abdominal normothermic regional perfusion for extended criteria donors in liver transplantation: a single center comparison	Roberto Broere	Received

FRI-473	The impact of extending preservation time of extended criteria liver grafts through hypothermic oxygenated machine perfusion prior to normothermic machine perfusion on viability assessment and clinical outcomes	Roberto Broere	Received

FRI-476	Triglyceride-based insulin resistance indices and post-transplantation diabetes mellitus after liver transplantation	Mateo Chvatal-Medina	Received

WED-476	Prevalence, risk factors, and clinical outcomes of micronutrient deficiencies in patients with cirrhosis: a prospective cohort study	&3660;&3660;Narisorn Lakananurak	Received

FRI-477	Triglyceride-rich lipoprotein cholesterol and risk of post-transplant diabetes in liver transplant recipients	Mateo Chvatal-Medina	Received

FRI-478	Synergism of trimethylamine n-oxide and lipoprotein insulin resistance with post-transplantation diabetes after liver transplant	Mateo Chvatal-Medina	Received

WED-478	Shear wave elastography combined with ALBI score enhances prediction of hepatic decompensation in advanced chronic liver disease	Jaejun Lee	Received

THU-480	High incidence and clinical relevance of concomitant Hepatopulmonary Syndrome among Patients with Portopulmonary Hypertension	Jendrik Peters	Received

WED-492	Phase angle as a predictor of mortality in patients with liver cirrhosis	Lenka Nosáková	Received

WED-497	Periprocedural bleeding in patients with cirrhosis: a prospective study	Adonis Protopapas	Received

FRI-498	Warming up for success: controlled oxygenated rewarming prior to normothermic liver perfusion	Roberto Broere	Received

SAT-500	Fairness-aware machine learning predicts 30-day mortality in vietnamese patients with decompensated cirrhosis	hien tran	Received

TOP-502	Longitudinal assessment of body composition and its prognostic impact after TIPS in cirrhosis: a prospective multicenter study (NutriTIPS group)	Simone Di Cola	Received

TOP-504	Liver and spleen stiffness measurements by vibration – controlled transient elastography predict liver-related outcomes of patients with porto-sinusoidal vascular disorder	Lucile Moga	Received

THU-505	Decreases in spleen stiffness assessed via vibration-controlled transient elastography at 100Hz upon chronic NSBB treatment do not predict HVPG response: results from a european multicenter study	Paul Thöne	Received

WED-506	Influence of albumin treatment duration on outcome of terlipressin therapy in patients with hepatorenal syndrome-acute kidney injury (HRS-AKI)	Eva Maria Schleicher	Received

FRI-508	Continuous glucose monitoring in liver transplant recipients in the intensive care unit: a randomized clinical trial cohort	Richie Alexander Inge Cox	Received

THU-510	Integrating gut microbiota and clinical parameters to predict beta-blocker response and portal pressure in patients with cirrhosis	Peishan wu	Received

WED-510	Differentiation of minimal and grade 1 hepatic encephalopathy using neurophysiological, neuropsychological, magnetic resonance spectroscopic, and systemic inflammatory parameters	Barjesh Sharma	Received

THU-511	Effects of early placement of transjugular portosystemic shunts in patients with gastric fundal variceal bleeding: a multicenter cohort study	Jie Xue	Received

FRI-511	Sex-based inequities in liver transplant access associated with jaffe creatinine measurement bias: an analysis from the scientific registry of transplant recipients data	Eda Kaya	Received

SAT-512	Potential of reflex testing with the CORE model triggered by liver enzyme abnormalities to improve risk prediction in the general population	Fredrik berg	Received

WED-515	Early mortality prediction in cirrhotic patients presenting to the emergency department: the CIRR-SOS score	Leonardo Stella	Received

THU-515	Interventional embolization of spontaneous portosystemic shunts improves survival by reducing further decompensation in selected patients with decompensated cirrhosis: a retrospective matched analysis	Hongbin Zhu	Received

TOP-520	Rejection-associated transcripts distinguish between different types of rejection after liver transplantation	Alejandro Campos Murguía	Received

SAT-522	Diagnostic performance of the ELF score for liver fibrosis staging in chronic liver disease: a comparative study with FibroScan, serum markers, and liver biopsy	Tatsuya Fujino	Received

WED-524	Active smoking is linked to persisting systemic inflammation and higher mortality after TIPS	Tammo Tergast	Received

FRI-524	Basiliximab preserves renal function after liver transplantation without increasing rejection or graft loss	Dorothy Liu	Received

FRI-525	Time-adjusted analysis of cumulative immunosuppression and hepatocellular carcinoma recurrence risk after liver transplantation	Dorothy Liu	Received

FRI-526	Multidisciplinary follow-up after liver transplantation: diagnostic yield and impact on cancer and cardiovascular outcomes	Erica Nicola Lynch	Received

THU-527	Social nurse interventions may reduce mortality in patients with acute decompensated liver cirrhosis	Palle Bager	Received

FRI-528	Outcomes of everolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma with or without steroid induction	Bianca Magro	Received

THU-529	Glypican 3-targeted antigen-specific fluorescent imaging enhances real-time intraoperative tumor identification in hepatocellular carcinoma: a translational study	Shuhei Kanda	Received

FRI-529	Who drops out? Preoperative prediction of hepatic hypertrophy techniques failure from the IGROWtoH registry	cecilia maina	Received

WED-529	Severity at diagnosis and progression in chronic liver disease by aetiology: a nationwide cohort study of 146,654 individuals in Sweden, 2002–2022	Juan Vaz	Received

SAT-530	A machine learning approach to non-invasively predict hepatic decompensation in compensated advanced chronic liver disease: the CIRI model	Georg Kramer	Received

WED-531	Optimal glycaemic targets to prevent major adverse cardiovascular events and risk of hypoglycaemia in patients with type 2 diabetes and cirrhosis	Mary Yue Wang	Received

SAT-531	Association between small intestinal bacterial overgrowth and chronic liver disease in patients with functional gastrointestinal disorders: a cross-sectional study in southern Vietnam	Ngan Le Thanh Quynh	Received

TOP-535	Barriers and facilitators in alcohol-related care pathways: findings from a qualitative interview study	Lea Ladegaard Grnkjr	Received

TOP-536	Conceptual development of an advanced practice nurse role for patients living with liver cirrhosis in a Swiss health care system	Jasmin Herzog	Received

WED-537	Targeted albumin therapy for recompensation in decompensated HBV-related cirrhosis: baseline characteristics of a multicenter randomized trial	Wanting Yang	Received

SAT-537	Nurse-led clinics improve hepatocellular carcinoma surveillance rates and survival in patients with cirrhosis	Mohammad Malik	Received

FRI-538	Cross-modality validation of 90% pathological response as a predictor of long-term survival in early-stage HCC	Mzamo Mbelle	Received

THU-546	LivR Well 2.0 - Nourishing a hungry liver: interim results	Sophie Page	Received

WED-547	FibroScan® insights: lifestyle change and liver health in primary biliary cholangitis	Louise Campbell	Received

FRI-547	Accuracy, feasibility, and nursing workload of continuous glucose monitoring in liver transplant recipients in the intensive care unit	Marc Pañero Moreno	Received

SAT-549	Prognostic value of handgrip strength in 1,294 japanese patients with liver cirrhosis: a large-scale multicenter cohort study from the NHO network	Hiroshi Yatsuhashi	Received

WED-549	Feedback meetings as a method to involve patients with alcohol-related liver cirrhosis and their relatives	Marie Christiansen	Received

TOP-551	Intrahepatic cccDNA Activity in HBsAg-Negative HBV Carriers and Its Association with HCC Risk	Yanfei Feng	Received

THU-553	Early health-related quality of life decline and hypoalbuminaemia predict outcomes in advanced hepatocellular carcinoma treated with atezolizumab–bevacizumab	Masako Shomura	Received

THU-554	Joint consultations during transition: perspectives of young adults with rare liver diseases	Janne Suykens	Received

THU-555	Real-world nutritional management and outcomes in alcohol-associated hepatitis: a comparison of adherence to guidelines and short-term mortality between two centers	Erica Wajntraub Bakszt	Received

THU-556	A review of terlipressin use in hepatorenal syndrome-acute kidney injury across 18 hospitals in the United Kingdom: Can we "CONFIRM" a change in practice?	(Leslie) Chun Man Wong	Received

THU-558	Small interfering RNA targeting all hepatitis B virus transcripts rapidly decreases the levels of hepatitis D virus in serum but not in the liver of HBV/HDV coinfected humanized mice	Johannes Bächer	Received

FRI-558	Excluding ascites from the GEMA-Na score does not impact outcome predictions in liver transplant candidates	Manuel Luis Rodriguez Peralvarez	Received

THU-559	HDV propagates by hijacking a non-canonical, lysosome-derived exosomal pathway independent of HBV	Enkhtuul Batbold	Received

WED-560	Improvement of patient satisfaction via implementation of a specialist nurse for patients with hepatocellular carcinoma – second interim analysis of the HCC care nurse pilot study	Larissa Pajancic	Received

THU-562	Study on the immunomodulatory effects and mechanisms of the traditional chinese medicine formula Tiaoganbuxuyidu against HBV in mice	Fan-E Cheng	Received

SAT-564	Management of chronic hepatitis B in people with human immunodeficiency virus infection in Europe: real-world evidence from Spain and Germany	PABLO RYAN	Received

TOP-566	Hepatitis B core–related antigen predicts immune-active transition in HBeAg-negative indeterminate chronic hepatitis B	Hsing-Yu Yeh	Received

TOP-567	AASLD–EASL zone ALT associated with higher risk of HCC and liver-related mortality inchronic hepatitis B patients	Tai-Chung Tseng	Received

THU-569	The mechanism of HSP90AB1 binding to hepatitis B surface antigen driving the progression of HBV-related hepatocellular carcinoma through chaperone-mediated autophagy	Shuangsuo Dang	Received

SAT-572	Durability of functional cure in chronic hepatitis B: a systematic review and meta-analysis	Yuxing Chen	Received

SAT-573	Seroprevalence and clinical characteristics of hepatitis d virus infection in korean patients with chronic hepatitis B and HBV-related hepatocellular carcinoma	Gwang Hyeon Choi	Received

SAT-576	Hepatitis B virus genotype distribution and viral load patterns in African immigrants to Canada	Curtis Cooper	Received

THU-585	Bulevirtide treatment reduces bystander activation of CD8+ T cells in chronic hepatitis D virus infection	Reem Hoblos	Received

FRI-588	Real-world effectiveness of antiviral therapy for chronic HBV infection in Africa: HEPSANET analysis	Kalisha Bheemraj	Received

THU-588	Acute hepatitis E virus infection in asymptomatic blood donors is characterized by constrained intra-host diversity and temporal mutational signatures	Saskia Janshoff	Received

SAT-589	High diagnostic value of transient elastography for the diagnosis of advanced fibrosis and cirrhosis in patients with hepatitis D virus infection	Anna Hahn	Received

FRI-591	Peginterferon alfa-2b–based therapy achieves higher HBsAg Loss in high-risk chronic hepatitis B patients: a prospective multicenter cohort study	Shuangsuo Dang	Received

SAT-593	Impact of cardiometabolic risk factors control in patients with chronic hepatitis B treated with nucleos(t)ide analogues	Karen Cheuk-Ying Ho	Received

WED-595	Antiviral effect and safety of terbinafine in chronic hepatitis B: results of a phase 1b study	Diederick van Doorn	Received

FRI-595	Validation of a sequencing-based HBV genotyping assay with serological backup for DNA-suppressed patients	Sanne Gils	Received

SAT-602	Real-world experience of 25 years of Lamivudine therapy: highlighting favorable long-term outcomes in chronic hepatitis B	Jaejun Lee	Received

FRI-602	Impact of the NTCP rs17556915 polymorphism on disease severity and bulevirtide treatment response in chronic hepatitis D: a multicentre real-world study	Yu Ri Im	Received

WED-605	From cure to complexity: post-SVR liver and metabolic trajectories in diabetic patients	Clelia Asero	Received

THU-606	Antisense oligonucleotide-based strategy to target hepatitis delta virus infections	Julie LUCIFORA	Received

FRI-606	Pipecolic acid–associated amino acid remodeling predicts functional cure in nucleoside analogue–experienced chronic hepatitis B treated with pegylated interferon alpha plus programmed cell death protein 1 blockade	Yaping Li	Received

SAT-608	Genetic diversification in hepatitis Delta antigen and ribozyme correlates with altered virological and biochemical markers and may inform novel therapeutic targets	Alessia Magnapera	Received

WED-610	Cumulative metformin exposure and risk of hepatocellular carcinoma after hepatitis C cure in a multicentre cohort	Henar Calvo Sánchez	Received

WED-617	Hepatic and extrahepatic malignancies in hepatitis C virus-infected patients with cirrhosis treated with direct-acting antivirals in long-term observation	Krystyna Dobrowolska	Received

WED-618	Evaluation of clinical performance and utility of the combined HCV antigen-antibody assay (HCV Duo)	Tatsuya Fujino	Received

THU-621	Verification and validation data of the CE-IVD marked AltoStar® HDV RT-PCR Kit 1.5 for monitoring HDV RNA viral load in plasma and serum samples	Karin ROTTENGATTER	Received

THU-622	A novel human liver chimeric mouse model to study Hepatitis B virus DNA integration	Melina Schäfer	Received

THU-623	Arrayed human and porcine ISG screens identify hepatitis E virus host restriction factors	Sarah Schlienkamp	Received

SAT-623	Quantitative HBsAg identifies individuals unlikely to achieve spontaneous functional cure of chronic hepatitis B	Juan carlos Ruiz cobo	Received

WED-625	The association of liver stiffness measurement with liver-related complications in chronic hepatitis C infection: a retrospective study in Thailand	Pemika Manassevee	Received

WED-626	Hepatocellular carcinoma surveillance among chronic hepatitis C patients after successful sustained virologic response: a systematic review and meta-analysis of economic evaluation studies	Soe Thiha Maung	Received

THU-627	Hepatocellular carcinoma is a viral reservoir during hepatitis C treatment with direct-acting antivirals	Mario Jorge Silva	Received

SAT-628	Long-term risk of hepatocellular carcinoma in strictly defined immune tolerant patients with chronic hepatitis B - Results from the global RADICAL consortium	Lisa van Velsen	Received

THU-628	The miR-4461–FGA regulatory axis characterises hepatitis B virus infection and HBV-related hepatocarcinogenesis	Masaya Sugiyama	Received

SAT-633	The impact of longitudinal hepatitis B virus genotypic diversity and viral dynamics on hepatocellular carcinoma risk in chronic hepatitis B	Ding-Lian Wang	Received

WED-634	HCV screening and prevalence among children with neonatal abstinence syndrome and their mothers - underserved at-risk populations in the era of HCV elimination	Caroline Schwarz	Received

SAT-637	Integrated model nurse clinic reduces adverse pregnancy outcomes of pregnant women with chronic hepatitis B	Grace Wong	Received

WED-643	COVID-19 pandemic had minimal impact on the effort spent on the enhancement programme of treatment coverage for all adult patients with chronic hepatitis C virus (HCV) infection	Grace Wong	Received

WED-644	Impact of sustained virological response on the prognosis of patients with HCV-related cirrhosis: a large-scale multicenter cohort study from the pre-and post-DAA eras	Hiroshi Yatsuhashi	Received

EASL Congress 2026

27-30 May, Barcelona

Help Line

Homepage

Personal Area

Search and consult posters online
in an exclusive section
for each poster

ACTIVE FROM 27/05/2026 TO 30/05/2026

Poster
Gallery

Upload
Poster

Featured Poster

Vote poster

Poster Discussion
Forum

DOI: 10.3252/pso.eu.EASL2026.2026



		Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress.

About us

Terms and Conditions